Alzheimer's Research UK

What Alzheimer's Research UK does

Alzheimer's Research UK is the United Kingdom's leading dementia research charity, established in 1998 and headquartered in Great Addington with a national presence including offices in London and Manchester. The organization funds and coordinates world-class dementia research across the full pipeline — from early-stage pilot studies and translational drug discovery through clinical fellowships and phase III trials — having cumulatively invested more than £270 million across over 1,450 projects in collaboration with researchers in more than 110 countries. Its core scientific platform is the Drug Discovery Alliance, a £45M-renewed network anchoring three flagship university institutes at Cambridge, Oxford, and UCL with over 80 scientists, which has explored more than 80 drug targets, advanced 15 to animal studies, and produced at least one spinout (AstronauTx, founded 2019).

The charity's product set is not commercial but programmatic: Major Projects funding (£4M+), Clinical Fellowships (£2.6M for six), Pilot Projects (£680,000 for ten), and the Drug Discovery Alliance itself, supplemented by an annual research conference convening 700+ researchers. The revenue model is exclusively donations-based — public donations, corporate cause-marketing partnerships (notably a 10-year Dyson/James Dyson Foundation relationship worth £1M cumulative and a Dobbies Garden Centres partnership that raised £235,000 in its first year), and fundraising events. Pricing is non-applicable because the charity provides research funding, public awareness campaigns (e.g., 'Think Brain Health', 'Dementia Unseen'), and policy advocacy free of charge to its ultimate beneficiaries: people affected by dementia, their families, and the UK research community.

Strategically, Alzheimer's Research UK is positioning itself as a translational engine rather than a pure grant-maker, evidenced by the DDA's explicit target of advancing at least one in-house drug into clinical trials within five years and the newly established Clinical Committee awarding fellowships. Governance includes former UK Prime Minister David Cameron as Chairman of the Board for EDoN (Early Detection of Neurodegenerative diseases) and Timothy Parry as Director of Communications & Brand. The charity is actively building policy influence through a 45+ organization coalition pushing the UK government for a 10-year national dementia ambition within the Modern Service Framework, targeting structural gaps such as the fact that only 5% of UK dementia patients currently access biomarker testing compared to ~30% in Italy.

Name

Alzheimer's Research UK

Legal name

Alzheimer's Research UK

Website

https://dementiablog.org

Company type

Private

Founded year

1998

Operating status

Operating

Short description

Alzheimer's Research UK is the UK's leading dementia research charity, funding and coordinating the full dementia research pipeline from early-stage drug discovery through clinical trials, having invested over £270 million across 1,450+ projects since 1998. It serves people affected by dementia, their families, and the UK research community through grant programs, the Drug Discovery Alliance at Cambridge/Oxford/UCL, and policy advocacy.

Ownership category

akta.pro rank

Product category

Dementia Research Charity

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Dementia research funding
• Charitable research grants
• Drug discovery alliance
• Neurological disease research
• Public health advocacy

Headquarters

HQ city

Great Addington

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Others, Operations, Personnel, Marketing or Sales

Revenue model

1. Charitable donations and fundraising: Alzheimer's Research UK generates revenue primarily through public donations, corporate partnerships, and fundraising campaigns. Notable partnerships include Dobbies Garden Centres (£235,000 raised in first year) and Dyson (£1 million raised over 10 years through employee fundraising and machine donations).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Alzheimer's Research UK is a UK-based charity that funds and coordinates dementia research across the country. Its core activities are grant-making to universities (Major Projects, Clinical Fellowships, Pilot Projects), operating the Drug Discovery Alliance — a network of three drug discovery institutes at Cambridge, Oxford, and UCL — and running public awareness campaigns such as 'Think Brain Health' and 'Dementia Unseen'. The organization is funded primarily through donations, corporate partnerships, and fundraising campaigns rather than commercial product sales.

Product overview

Alzheimer's Research UK operates as a research funding charity rather than a traditional product company. Its core offerings consist of research funding programs supporting dementia research across the UK: the Drug Discovery Alliance (a coordinated network at Cambridge, Oxford, and UCL universities), Major Projects funding for large-scale research initiatives, Clinical Fellowships to build clinical research capacity, and Pilot Projects for innovative research approaches. The organization also runs public awareness campaigns including the Think Brain Health campaign, and hosts annual research conferences bringing together hundreds of researchers. All offerings function as charitable programs rather than commercial products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Discovery Alliance
• Major Projects Funding
• Clinical Fellowships
• Pilot Projects Funding
• Think Brain Health Campaign

Quantifiable outcome

• 35% of cells from frontal cortex of Alzheimer's patients showed signs of karyoptosis vs. only 15% in healthy aged controls (research funded/partnership)
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core, notable and flagship.

• King's College London and UK Dementia Research InstitutecoreStrategic or Co-development Partner · 25 June 2026Researchers from King's College London and the UK Dementia Research Institute identified a new mechanism of cell death called karyoptosis in brains of patients with Alzheimer's disease and frontotemporal dementia, providing a link between toxic protein accumulation and neuronal loss. Findings offer a new therapeutic target for developing treatments.
• Dobbies Garden CentresnotableGTM or Marketing Partner · 10 June 2026National charity partnership launched in March 2025, raising £235,000 in the first year — more than triple the original target. Funds support dementia research and public awareness campaigns. The partnership highlights the benefits of gardening for brain health and is linked to the Think Brain Health campaign. Second-year initiatives include sponsorship of Edinburgh's Walk for a Cure and special plant purchase donations.
• Alzheimer's Society and Dementia UKflagshipStrategic or Co-development Partner · 21 May 2026Alzheimer's Research UK joined with Alzheimer's Society and Dementia UK, along with 45 other health, research, and social care organizations, to publish an open letter urging the UK Secretary of State for Health and Social Care to set a transformative 10-year national ambition within the forthcoming Modern Service Framework for Dementia.
• UCL Alzheimer's Research UK Drug Discovery InstituteflagshipStrategic or Co-development Partner · 5 March 2026The institute received a £15 million investment as part of a £45 million funding round that also includes institutes at Cambridge and Oxford universities. The funding aims to accelerate the development of new dementia treatments, supporting drug discovery research and training the next generation of medicine makers. The institute launched in 2015, with its first spinout company AstronauTx founded in 2019.
• Drug Discovery Alliance (Cambridge, Oxford, UCL)flagshipStrategic or Co-development Partner · 25 February 2026The UK's largest network of drug discovery researchers in neurodegeneration, bringing together three research centres at the Universities of Cambridge, Oxford, and UCL with over 80 scientists. The five-year £45 million renewal (announced February 2026) aims to advance at least one DDA-developed drug into clinical trials within five years. Over the past decade, the DDA explored more than 80 potential drug targets, with 15 progressing to animal studies.
• James Dyson FoundationnotableGTM or Marketing Partner · 1 January 2025Ten-year partnership (celebrated in 2025) with Dyson and the James Dyson Foundation that collectively raised over £1 million for dementia research. The James Dyson Foundation match-funded employee fundraising efforts throughout the decade, while Dyson donated £50,000 worth of machines that helped raise an additional £611,000 through supporter events. Partnership set to continue into 2026.
• University of BristolnotableStrategic or Co-development PartnerUniversity of Bristol project funded through the £9.5 million investment, using 3D imaging to study brain blood vessel changes in dementia research.
• University of NottinghamnotableStrategic or Co-development PartnerUniversity of Nottingham project funded through the £9.5 million investment, developing a blood test to distinguish between dementia types.
• Clinical Research Community (UK)coreStrategic or Co-development PartnerThe Clinical Committee awarded £2.6 million to fund six Clinical Fellowships aimed at strengthening the UK's clinical research capacity in dementia, as part of the broader £9.5 million investment announced in June 2026. The 2026 annual research conference featured sessions on clinical trials including phase III TRONTIER 1 and 2 studies on 'brainshuttle' technology.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Alzheimer's Society: UK's largest dementia charity, funding over £18.5M of dementia research and innovation in 2025 while also operating a national helpline and local services. Directly comparable mission (dementia research and support) and joint coalition partner with Alzheimer's Research UK on the Modern Service Framework campaign.
• Dementia UK: UK charity specializing in dementia care through its Admiral Nurse service. Shares the same donor pool and policy advocacy agenda as Alzheimer's Research UK, and is a named co-signatory of the Modern Service Framework open letter alongside the subject company.
• UK Dementia Research Institute (UK DRI): National institute hosted across multiple UK universities that funds and conducts discovery neuroscience and translational dementia research. Co-funds research projects (e.g. karyoptosis work with King's College London) and is a near-substitute for the research-pipeline role the Drug Discovery Alliance plays.
• Alzheimer's Drug Discovery Foundation (ADDF): US-based charity that funds translational drug discovery for Alzheimer's and related dementias, including through academic drug discovery institutes. Closely comparable to the Drug Discovery Alliance model in mission and grantmaking focus on early-stage therapeutic development.
• Cure Alzheimer's Fund: US nonprofit that exclusively funds Alzheimer's disease research with a focus on understanding disease mechanisms and accelerating drug discovery. Comparable as a research-only funder, though smaller in scale than Alzheimer's Research UK.
• BrightFocus Foundation: US nonprofit that issues research grants for Alzheimer's, macular degeneration and glaucoma, including early-stage investigator awards. Comparable grantmaking model and disease-specific research focus, particularly on early-stage and translational science.

Broad incumbents

• Alzheimer's Association: The largest US dementia-focused nonprofit, funding research, providing care and support, and leading national advocacy. Operates at significantly larger scale than Alzheimer's Research UK but pursues an analogous research-grantmaking, awareness and policy mission.
• Wellcome Trust: Large UK-based charitable foundation that funds biomedical and health research, including neuroscience and mental health. Not dementia-specific but a major competitor for the same academic researchers, talent and large-scale research grants that Alzheimer's Research UK supports.

Emerging players

• Michael J. Fox Foundation for Parkinson's Research: Highly regarded disease-specific research charity that has built a sophisticated translational and clinical-trial funding model in neurodegeneration. Indirect peer — different disease focus (Parkinson's) but closely analogous operating model and high bar for research charity benchmarking.
• Banner Alzheimer's Institute: US nonprofit research institute focused on Alzheimer's prevention trials and biomarker science. Comparable in mission around translational research and clinical-trial readiness, though structured as an operating research institute rather than a pure grantmaker.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

• Xx.com/ARUKnews
• Facebookfacebook.com/AlzheimersResearchUK

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheimer's Research UK